Bicalutamide
Bicalutamide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Castration Levels of Testosterone、Metastatic Prostatic Adenocarcinoma、Stage IV Prostate Cancer AJCC v8、Stage IVA Prostate Cancer AJCC v8。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
21 项
全球在招研究
5 项
已进入 III/IV 期
12 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- SWOG Cancer Research Network
- University of Wisconsin, Madison
- Marco Lorenzo Bonu
- City of Hope Medical Center
- The Methodist Hospital Research Institute
- Virginia Commonwealth University
- University of California, San Francisco
- CHU de Quebec-Universite Laval
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
- Golden State Medical Supply, Inc.
- ANI Pharmaceuticals, Inc.
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Chile、Colombia、Mexico、瑞士、意大利、加拿大、西班牙、中国、比利时、Bulgaria、荷兰
正在招募患者的 Bicalutamide 研究
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
III 期招募中美国ChileColombiaMexicoNCT03678025SRT Versus SRT+ADT in Prostate Cancer
III 期招募中意大利NCT05019846Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
II 期招募中美国NCT04734730Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
I 期 / II 期招募中美国NCT07182279Autonomic and Renal Contributions to Hypertension With ADT
IV 期招募中美国NCT07848828Bicalutamide Therapy in Young Women With NAFLD and PCOS
I 期招募中美国NCT05979389A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
II 期招募中加拿大NCT05327647Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
II 期招募中美国NCT07455903Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC
I 期 / II 期招募中美国NCT06222593REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
III 期招募中美国NCT06650579A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
I 期招募中美国NCT05521698Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
II 期招募中美国NCT03541928Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
III 期招募中西班牙NCT05781217Androgen-responsive POSLUMA-guided Intra-prostatic Boost
II 期招募中美国NCT07393867An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment
不适用招募中中国NCT07538843Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
II 期招募中比利时NCT06365788A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer
I 期招募中BulgariaNCT07783282Phase II Dutasteride in Combination With CAB vs CAB in SDC
II 期招募中荷兰NCT05513365Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
I 期 / II 期招募中美国NCT05095207A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease
II 期招募中中国NCT07117851Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
II 期招募中中国NCT06145308
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。